fig2
![Pharmacogenetic and pharmacogenomic discovery strategies](https://image.oaes.cc/866ad8d2-af6e-4525-a533-49ed80b40555/3059.fig.2.jpg)
Figure 2. The efficiency of discovery of novel pharmacogenetic/pharmacogenomic biomarkers, modified from[27]. The combined expected impact of genomic variants on disease occurrence and genomic diagnostics is indicated (light green: low; deep green: high)